ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects

This is a Phase 1, open-label, single center, non-randomized study to evaluate the absorption, distribution, metabolism and excretion (ADME) of an oral solution of radiolabeled Ibrexafungerp following repeat administration in healthy male subjects. All subjects will undergo preliminary screening procedures, will remain the clinical unit for approximately 26 days and will receive radiolabeled Ibrexafungerp, orally for 3 days.

Inclusion Criteria:Healthy males aged 30 to 65 years willing and able to sign and informed consent.Exclusion Criteria:Clinically significant medical history or concurrent medical conditions included but not limited to infections, liver or kidney diseaseUse of certain concomitant medicationsHistory of smoking or alcohol abuse